A Haemostasis partner to trust

MediRox is one of the market leaders in Scandinavia among the producers of haemostasis diagnostic reagents and controls.

See all products

R & D

A true innovation centre

Production

High coordination for the highest quality

Latest News

Årsredovisning för 2016

24 May 2017

MediRox årsredovisning för räkenskapsåret 2016 finns nu tillgänglig.

Kallelse till årsstämma

19 May 2017

Aktieägarna i MediRox AB (publ), org. nr 556552-4054, kallas härmed till årsstämma tisdagen den 20 juni 2017, klockan 14:00 på Horsvik konferens i Studsvik i konferensrum Hartsö.

Årsstämmodatum 2017 flyttat.

14 February 2017

Årsstämmodatum 2017 flyttat till 2017-06-20

Pressrelease tidpunkt för avnotering

16 December 2016

Enligt tidigare styrelsebeslut om avnotering av MediRox aktier från AktieTorget har datum för avnotering satts till den 22 december 2016. Sista dag för handel med bolagets aktier är 21 december 2016.

Pressrelease Avnotering

15 December 2016

MediRox beslutar om avnotering efter att Ahead Global äger mer än 90% av bolaget.

Coagulation reagents

MRX APTT

Liquid compontent kits containing phospholipid extract and silica contact activator. Sensitive to heparin as well as factors and insensitive to lupus anticoagulant.

MRX Fib Clauss

Lyophilised reagents for quantifying fibrinogen in human citrated plasma, according to the Clauss method.

MRX D-Dimer

Latex-based liquid component kits for quantifying D-dimer fragments in human citrated plasma using readers with wavelengths 350-900nm.

MRX AT

FXa-based chromogenic assay consisting of liquid components for quantifying functional Antithrombin activity in human citrated plasma.

MRX Owren's PT

The predominantly used PT method in Scandinavia due to the high sensitivity to interferences. The assay can be used with both whole blood and plasma.

MRX PT Quick

PT reagent from rabbit brain origin with an ISI ~1 for responsive determination of Prothrombin Time in citrated human plasma.

MRX Thrombin Time

Two different lyophilised reagents for detection of fibrinogen abnormalities, and the presence of heparin and other thrombin inhibitors in human citrated plasma.